Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Castration-resistant , CYP 17 Inhibitor-naïve Prostate Cancer : Results from Extended Follow-up of the ARADES Trial

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

  2019cited by this paper
• Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer.

  2016cited by this paper
• Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

  2016cited by this paper
• Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.

  2015cited by this paper
• Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

  2015cited by this paper
• Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

  2015cited by this paper
• Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

  2015cited by this paper
• Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

  2015cited by this paper
• ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

  2015cited by this paper
• ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).

  2015cited by this paper
• Psychological effects of androgen‐deprivation therapy on men with prostate cancer and their partners

  2015cited by this paper
• Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

  2014influential reference
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

  2014cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Prostate cancer: ESMO Consensus Conference Guidelines 2012.

  2013cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Population-based study on use of chemotherapy in men with castration resistant prostate cancer

  2013influential reference
• Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

  2013cited by this paper
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

  2012cited by this paper
• Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Targeting Continued Androgen Receptor Signaling in Prostate Cancer

  2011cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer

  2009cited by this paper
• Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.

  2009cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008influential reference
• Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer

  2006cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer

  1995cited by this paper

• No citing papers are available for this paper.